Bup Feeds

Feasibility of radial and circumferential strain analysis using 2D speckle tracking echocardiography in cats.

Buprenorphine Research (PubMed) - Fri, 11/07/2014 - 6:00am

Feasibility of radial and circumferential strain analysis using 2D speckle tracking echocardiography in cats.

J Vet Med Sci. 2014 Nov 6;

Authors: Takano H, Isogai T, Aoki T, Wakao Y, Fujii Y

Abstract
The purpose of the present study is to investigate the feasibility of strain analysis using speckle tracking echocardiography (STE) in cats and to evaluate STE variables in cats with hypertrophic cardiomyopathy (HCM). Sixteen clinically healthy cats and 17 cats with HCM were used. Radial and circumferential strain and strain rate variables in healthy cats were measured using STE to assess the feasibility. Comparisons of global strain and strain variables between healthy cats and cats with HCM were performed. Segmental assessments of left ventricle (LV) wall for strain and strain rate variables in cats with HCM were also performed. As a result, technically adequate images were obtained in 97.6% of the segments for STE analysis. Sedation using buprenorphine and acepromazine did not affect any global strain nor strain rate variable. In LV segments of cats with HCM, reduced segmental radial strain and strain rate variables had significantly related with segmental LV hypertrophy. It is concluded that STE analysis using short axis images of LV appeared to be clinically feasible in cats, having the possibility to be useful for detecting myocardial dysfunctions in cats with diseased heart.

PMID: 25373881 [PubMed - as supplied by publisher]

Categories: Bup Feeds

Social network support for individuals receiving opiate substitution treatment and its association with treatment progress.

Buprenorphine Research (PubMed) - Fri, 11/07/2014 - 6:00am
Related Articles

Social network support for individuals receiving opiate substitution treatment and its association with treatment progress.

Eur Addict Res. 2013;19(4):211-21

Authors: Day E, Copello A, Karia M, Roche J, Grewal P, George S, Haque S, Chohan G

Abstract
BACKGROUND/AIMS: Social networks have been hypothesized to protect people from the harmful effects of stress, but may also provide dysfunctional role models and provide cues associated with drug use. This study describes the range, type and level of social support available to patients engaged in UK opiate substitution treatment (OST) programmes, and explores the association between network factors and continued use of illicit heroin.
METHODS: A cross-sectional survey of a randomly selected sample of OST patients (n = 118) utilised measures of current substance use and social network structure and support.
RESULTS: More than half of the participants had used heroin in the previous month, and most described networks that were both supportive and positive about treatment. Multivariate analysis showed that the substance use involvement of network members was higher in those patients still using heroin, even when other treatment factors were controlled for.
CONCLUSION: There was a strong association between ongoing contact with other drug users and continued use of illicit heroin in this treatment sample. Whilst there is potential for the involvement of social networks in treatment, future research needs to ascertain the exact nature of the relationship between social support and drug use.

PMID: 23391965 [PubMed - indexed for MEDLINE]

Categories: Bup Feeds

Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study.

Buprenorphine Research (PubMed) - Fri, 11/07/2014 - 6:00am
Related Articles

Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study.

Eur Addict Res. 2013;19(4):194-201

Authors: Skeie I, Brekke M, Clausen T, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H

Abstract
BACKGROUND/AIMS: Some patients on opioid maintenance treatment (OMT) leave treatment temporarily or permanently. This study investigated whether patients interrupting their OMT differed from non-interrupters in sociodemographic and drug-use characteristics and examined acute/sub-acute somatic morbidity among the interrupters, prior to, during, and after OMT.
METHODS: Cohort design. OBSERVATION PERIOD: 5 years prior to, up to first 5 years during, and up to 5 years after interruption of OMT.
PARTICIPANTS: The sample (n = 200) comprised 51 OMT interrupters and 149 non-interrupters. Data on patient characteristics were obtained from interviews and OMT register information. Data on somatic morbidity were gathered from hospital records.
MEASUREMENTS: Key patient characteristics among OMT interrupters and non-interrupters. Incidence rates of acute and sub-acute somatic disease incidents leading to hospital treatment (drug-related/non-drug-related/injuries) prior to/during/after OMT.
RESULTS: Interrupters and non-interrupters did not differ in sociodemographic characteristics, while longer duration of amphetamine and benzodiazepine dependence predicted OMT interruption. Interrupters scored significantly higher on drug-taking and overdose during OMT but still had a significant 41% reduction in drug-related treatment, episodes. After interruption of treatment, such episodes increased markedly and were 3.6 times more frequent during the first post-OMT year compared to the pre-OMT period (p < 0.001). This increase was highest during the first months after OMT interruption. 2-5 years after interruption there was no significant increase.
CONCLUSIONS: Increased somatic morbidity was found among OMT interrupters during the first year after OMT, and especially during the immediate post-treatment period.

PMID: 23257574 [PubMed - indexed for MEDLINE]

Categories: Bup Feeds

Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.

Buprenorphine Research (PubMed) - Wed, 11/05/2014 - 8:00am
Related Articles

Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.

J Psychoactive Drugs. 2014 Nov-Dec;46(5):427-35

Authors: Johnson B, Richert T

Abstract
Abstract Opioid substitution treatment (OST) is still controversial, despite positive results. The issue of diversion to the illicit drug market is a cornerstone in the criticism typically voiced against the treatment. Little research is available concerning how professionals who work in OST view the issue of diversion. In this article, we discuss existing ideas and attitudes toward diversion of methadone and buprenorphine among OST staff in Sweden. The article is based on semi-structured interviews with 25 professionals working in eight OST-programs in southern Sweden. Diversion was seen as a deleterious phenomenon by the interviewees. Three problematic aspects were highlighted: medical risks in the form of overdose fatalities and the recruitment of new opiate/opioid users; negative consequences for the legitimacy of OST; and moral objections, since diversion means that the patients remain in a criminal environment. However, positive aspects were also highlighted. Illicit methadone or buprenorphine is perceived as safer than heroin. In this way, diversion can fulfill a positive function; for instance, if there is a shortage of access to regular treatment. Patients who share their medication with opioid-dependent friends are seen as less culpable than those who sell to anyone for money.

PMID: 25364995 [PubMed - in process]

Categories: Bup Feeds

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study.

Buprenorphine Research (PubMed) - Wed, 11/05/2014 - 8:00am
Related Articles

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study.

J Psychoactive Drugs. 2014 November-December;46(5):412-426

Authors: Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W

Abstract
Abstract This study examines the barriers and facilitators of retention among patients receiving buprenorphine/naloxone at eight community-based opioid treatment programs across the United States. Participants (n = 105) were recruited up to three and a half years after having participated in a randomized clinical trial comparing the effect of buprenorphine/naloxone and methadone on liver function. Semi-structured interviews were conducted with 67 patients provided with buprenorphine/naloxone who had terminated early and 38 patients who had completed at least 24 weeks of the trial. Qualitative data were analyzed using the constant comparison method. Barriers to buprenorphine/naloxone retention that emerged included factors associated with: (1) the design of the clinical trial; (2) negative medication or treatment experience; and (3) personal circumstances. The facilitators comprised: (1) positive experience with the medication; (2) personal determination and commitment to complete; and (3) staff encouragement and support. The themes drawn from interviews highlight the importance of considering patients' prior experience with buprenorphine/naloxone and methadone, medication preference, personal circumstances, and motivation to abstain from illicit use or misuse of opioids, as these may influence retention. Ongoing education of patients and staff regarding buprenorphine/naloxone, especially in comparison to methadone, and support from staff and peers are essential.

PMID: 25364994 [PubMed - as supplied by publisher]

Categories: Bup Feeds

Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Buprenorphine Research (PubMed) - Wed, 11/05/2014 - 8:00am
Related Articles

Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

J Drug Issues. 2014 Jan;44(1):69-82

Authors: Mitchell SG, Gryczynski J, Kelly SM, O'Grady KE, Jaffe JH, Olsen YK, Schwartz RP

Abstract
This secondary analysis compared outcomes of African-American adults newly-admitted to buprenorphine treatment who were on parole and probation to patients who were not under criminal justice supervision. Buprenorphine patients (N=300) were randomly assigned to receive either Intensive Outpatient Treatment (IOP) or Standard Outpatient Treatment (OP) treatment and were assessed at baseline, 3- and 6-months. There were no differences between groups in treatment retention. Among probationers/parolees, IOP was associated with lower 3-month treatment retention compared to OP, but among participants not on probation/parole the relationship was reversed (p=.004). Both conditions showed significant declines in heroin and cocaine use, illegal activity, and in meeting DSM-IV criteria for opioid and cocaine dependence. Probationers/parolees reported lower frequency of illegal activities at 3-months compared to non-probationers/parolees (p=.007). Buprenorphine treatment should be made more widely available to individuals on parole/probation as they respond as well to treatment as patients not supervised by the criminal justice system.

PMID: 25364037 [PubMed - as supplied by publisher]

Categories: Bup Feeds

Striatal dopamine D1 and D2 receptors are differentially regulated following buprenorphine or methadone treatment.

Buprenorphine Research (PubMed) - Sun, 11/02/2014 - 8:30am
Related Articles

Striatal dopamine D1 and D2 receptors are differentially regulated following buprenorphine or methadone treatment.

Psychopharmacology (Berl). 2014 Oct 31;

Authors: Allouche S, Le Marec T, Coquerel A, Noble F, Marie N

Abstract
RATIONALE: Chronic administration of morphine induces adaptations in neurotransmission system such as the dopamine pathway, and these modifications could be influenced by the drug administration pattern. Methadone and buprenorphine are the two main opioid substitution therapies, and despite their protracted use in humans, no study has investigated their ability to regulate dopamine system after chronic exposure/withdrawal.
OBJECTIVES: We evaluated the consequences of two administration patterns of methadone and buprenorphine on striatal dopamine D1 (D1R) and D2 (D2R) receptor levels.
METHODS: Mice were treated with escalating doses of methadone or buprenorphine for 5 days either once daily (binge) or three times a day (TTD). D1R and D2R density in striatum was measured by autoradiography using [(3)H]-SCH23390 and [(3)H]-raclopride, respectively, at 1 (WD1), 14 (WD14), and 35 (WD35) days after the last opioid injection.
RESULTS: A downregulation of D1R was observed upon TTD administration of buprenorphine and binge methadone treatment while an increase of those receptor levels was detected both with binge buprenorphine and TTD methadone treatments. Concerning the D2R, we rather measured an early or late downregulation with both agonists and administration patterns.
CONCLUSIONS: Our results demonstrated that methadone and buprenorphine were able to differentially regulate dopamine receptor density depending on the withdrawal period and the administration pattern.

PMID: 25358852 [PubMed - as supplied by publisher]

Categories: Bup Feeds

23-year-old woman being treated for opioid dependence, unexpected weight gain.

Buprenorphine Research (PubMed) - Sun, 11/02/2014 - 8:30am
Related Articles

23-year-old woman being treated for opioid dependence, unexpected weight gain.

J Fam Pract. 2014 Jul;63(7):366-7

Authors: Chudgar NP, Greenblatt L

PMID: 25198209 [PubMed - indexed for MEDLINE]

Categories: Bup Feeds

Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway.

Buprenorphine Research (PubMed) - Sun, 11/02/2014 - 8:30am
Related Articles

Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway.

Eur Addict Res. 2014;20(2):59-65

Authors: Karlstad Ø, Furu K, Skurtveit S, Selmer R

Abstract
BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is a risk factor for the development of substance use disorders. Treatment of ADHD with psychostimulants in patients on opioid maintenance treatment (OMT) has been restricted in Norway. We examined the use of prescribed drugs for ADHD in OMT patients and assessed co-medication with other psychotropics.
METHODS: Data were drawn from the nationwide Norwegian Prescription Database (NorPD), which includes all prescriptions filled at pharmacies. The study population included subjects ≥18 years on OMT during 2008-2010.
RESULTS: In 2010, 6,116 patients received OMT and 2.8% of these also received ADHD drugs. This percentage is seven times greater than that in the gender- and age-specific general population of Norway. The prevalence was higher in the youngest patients, while there was no gender difference. Methylphenidate was the most commonly used drug for ADHD in OMT patients, followed by atomoxetine. 60% of OMT patients filled at least one prescription for antidepressants, anxiolytics or hypnotics, and percentages were similar for users and non-users of ADHD drugs.
CONCLUSION: Treatment with ADHD drugs was higher in OMT patients than expected from the general population, but was relatively low compared to the prevalence of ADHD in patients with substance use disorders reported in the literature.

PMID: 24080771 [PubMed - indexed for MEDLINE]

Categories: Bup Feeds

Pages

Subscribe to BupPractice aggregator - Bup Feeds